Nocturnal acid breakthrough: Clinical significance and management
Authors:
- 13 November 2006
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 21 (s5) , S125-S128
Abstract
Nocturnal acid breakthrough is seen in more than 70% of Helicobacter pylori‐negative patients taking long‐term proton pump inhibitors (PPI). It is defined as an intragastric pH of less than 4 for at least 60 consecutive minutes during the overnight period in patients on PPI therapy. It occurs as a result of the recovery of intragastric acidity. Nocturnal acid breakthrough can be clinically significant in patients with complicated gastroesophageal reflux disease, Barrett’s esophagus and esophageal motility disorders because of the potential for continued esophageal mucosal injury. To decrease nocturnal acid breakthrough, for patients on once daily PPI, treatment should be stepped up to twice daily. For patients already on twice daily PPI, nocturnal histamine‐2 receptor antagonists may be added, but the long‐term effectiveness remains debatable as patients may develop tolerance over the course of time. New PPI with a longer half‐life may decrease nocturnal acid breakthrough.Keywords
This publication has 23 references indexed in Scilit:
- Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazoleEuropean Journal of Gastroenterology & Hepatology, 2004
- Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthroughAlimentary Pharmacology & Therapeutics, 2004
- Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori -negative subjects: effects of different regimensJournal of Gastroenterology, 2003
- Nocturnal Acid Breakthrough: Clinical Significance and Correlation With Esophageal Acid ExposureAmerican Journal of Gastroenterology, 2003
- An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapyAlimentary Pharmacology & Therapeutics, 2002
- Oesophageal motility defects associated with nocturnal gastro‐oesophageal reflux on proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 1999
- Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pHAlimentary Pharmacology & Therapeutics, 1999
- Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg dailyAlimentary Pharmacology & Therapeutics, 1998
- Gastro‐oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 1998
- Nocturnal Recovery of Gastric Acid Secretion With Twice-Daily Dosing of Proton Pump InhibitorsAmerican Journal of Gastroenterology, 1998